Sign in

    Kiran Sritharan

    Research Analyst at Eight Capital

    Kiran Sritharan is an Associate Analyst at Eight Capital, specializing in equity research and coverage of emerging Canadian technology and media companies. He provides coverage on companies such as Sabio Holdings and Tribe Property Technologies, maintaining Buy ratings and delivering detailed analyses that highlight growth drivers and financial performance, including strong CTV/OTT revenue growth for Sabio Holdings and positive outlooks for Tribe's upside. Sritharan began his career in equity research in Toronto and has been with Eight Capital as an Associate Analyst, where he is noted for his thorough analysis and sector expertise, although public platforms do not track his forecast performance metrics or formal industry rankings. Professional credentials, such as FINRA registration or Canadian securities licenses, are not publicly listed for Sritharan.

    Kiran Sritharan's questions to Docebo (DCBO) leadership

    Kiran Sritharan's questions to Docebo (DCBO) leadership • Q4 2024

    Question

    Kiran Sritharan of TD Cowen asked about the expected contribution to 2025 ARR growth from new logos versus existing customers. He also questioned if the Agentic AI opportunity is included in the current TAM and how the company is staffed to develop it.

    Answer

    Interim CFO Brandon Farber reiterated that the company does not provide forward-looking NER but expects it to inflect up after Q1 2025 as rightsized customers begin to grow again. CEO Alessio Artuffo explained that while the Agentic AI strategy is nascent, the company is staffed with specialized talent from the Edugo acquisition and will continue to invest in AI engineering and product leaders to execute its vision.

    Ask Fintool Equity Research AI

    Kiran Sritharan's questions to Sabio Holdings (SABOF) leadership

    Kiran Sritharan's questions to Sabio Holdings (SABOF) leadership • Q3 2024

    Question

    Inquired about the magnitude of political spending in Q4 and the outlook for advocacy spending in 2025. Also asked about post-election conversations with core brand customers and the drivers behind the strong gross margin performance.

    Answer

    Executives stated that most political spending occurred in Q3 and that advocacy spending is expected to be strong in 2025. They noted that core customers remain confident due to a strong economy. The strong gross margin was attributed to their proprietary end-to-end tech stack, including App Science and direct supply integrations, which reduces external costs. However, they cautioned that future products like programmatic might have lower gross margins but higher EBITDA margins.

    Ask Fintool Equity Research AI

    Kiran Sritharan's questions to Healwell AI (HWAIF) leadership

    Kiran Sritharan's questions to Healwell AI (HWAIF) leadership • Q3 2024

    Question

    Kiran Sritharan, on for Adhir Kadve, asked if achieving the $100 million revenue run rate depends on a single large transaction, how the profitability goal influences M&A targets, and about recent developments at Pentavere driving its market recognition.

    Answer

    CEO Alexander Dobranowski explained they are evaluating a spectrum of M&A opportunities, including larger ones, while prioritizing targets that are EBITDA and cash flow positive to support the 2025 profitability goal. He attributed Pentavere's recent success to its integration into Healwell, which provided crucial access to the scale, data, and provider network of WELL Health.

    Ask Fintool Equity Research AI

    Kiran Sritharan's questions to Healwell AI (HWAIF) leadership • Q3 2024

    Question

    Kiran Sritharan, on for Adhir Kadve, asked if achieving the $100 million revenue run rate target depends on a single large transaction, how the profitability goal influences M&A target profiles, and what recent developments at Pentavere are driving its market recognition.

    Answer

    CEO Dr. Alexander Dobranowski explained that while Healwell is evaluating a spectrum of deals, including larger ones, the company is prioritizing targets that generate strong positive EBITDA and cash flow to ensure it meets its 2025 profitability mandate. He attributed Pentavere's recent success and validation directly to joining Healwell, which provided crucial access to the scale, data, and provider base of the WELL Health ecosystem.

    Ask Fintool Equity Research AI